Skip to Content

Posts tagged with "Drug Industry History"

  • Alzheimer's Disease

    Bernard Munos Rides Again

    I’ve been meaning to link to Matthew Herper’s piece on Bernard Munos and his ideas on what’s wrong with the drug business. Readers will recall several long discussions here about Munos and his published thoughts (Parts one, two, three and four). A take-home message: So how can companies avoid tossing away billions on medicines tha… Read More
  • Business and Markets

    A Former Pfizer Executive Finally Trashes Pfizer’s Strategy

    A number of readers have noted this piece by John LaMattina in Nature Reviews Drug Discovery. He is, of course, a former head of R&D at Pfizer, which makes the title of the article something of an attention-getter: “The impact of mergers on Pharmaceutical R&D”. Pfizer, for those of you just returning from a near-lightspeed… Read More
  • Drug Industry History

    Merck Moving Research From Rahway?

    I’ve heard from more than one person that Merck has decided to move most discovery research out of Rahway (in favor of the former Schering-Plough site in Kenilworth). Details are welcome in the comments from those with better information. That news does bring on end-of-an-era feelings, since they’ve been doing medicinal chemistry in Rah… Read More
  • Drug Development

    2011 Drug Approvals Are Up: We Rule, Right?

    I’ve been meaning to comment on this article from the Wall Street Journal – the authors take a look at the drug approval numbers so far this year, and speculate that the industry is turning around. Well, put me in the “not so fast” category. And I have plenty of company there. Neither Bruce Booth… Read More
  • Business and Markets

    The Secret History of Pfizer

    Here’s a fascinating account at Fortune of the departure of Jeff Kindler as Pfizer’s CEO. The magazine says that they interviewed over 100 people to round up the details, but some of these meetings only feature four or five people in a room, so that narrows things down a bit. It’s also a back-room history… Read More
  • Drug Assays

    Phenotypic Screening For the Win

    Here’s another new article in Nature Reviews Drug Discovery that (for once) isn’t titled something like “The Productivity Crisis in Drug Research: Hire Us And We’ll Consult Your Problems Away”. This one is a look back at where drugs have come from. Looking over drug approvals (259 of them) between 1999 and 2008, the au… Read More
  • Business and Markets

    Innovation and Return (Europe vs. the US)

    Here’s another look at the productivity problems in drug R&D. The authors are looking at attrition rates, development timelines, targets and therapeutic areas, and trying to find some trends to explain (or at least illuminate) what’s been going on. Their take? Attrition rates have been rising at all phases of drug development, and m… Read More
  • Biological News

    The Histamine Code, You Say?

    I’ve been meaning to link to John LaMattina’s blog for some time now. He’s a former R&D guy (and author of Drug Truths: Dispelling the Myths About Pharma R & D, which I reviewed here for Nature Chemistry), and he knows what he’s talking about when it comes to med-chem and drug development. Here he… Read More
  • Business and Markets

    Drug R&D Spending Now Down (But Look at the History)

    I hate to be such a shining beacon of happiness today, but this news can’t very well be ignored, can it? For the first time ever, total drug R&D spending seems to have declined: The global drug industry cut its research spending for the first time ever in 2010, after decades of relentless increases, and… Read More
  • Business and Markets

    Extreme Outsourcing

    My local NPR station had this report on this morning, on one-person drug companies. Can’t outsource much more than that! Here are the two companies profiled: LipimetiX and Deuteria. The former is using helical peptides to affect lipoprotein clearance, and the latter is (as you’d guess) in the deuterated-drug game, which I’ve most… Read More